ACBM
Acro Biomedical Co., Ltd.0.0007
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
42.03KP/E (TTM)
-Basic EPS (TTM)
-0.25Dividend Yield
0%Recent Filings
10-K
FY2025 results
Acro Biomedical posted FY2025 ended December 31, 2025 net loss of $101,146 on zero revenue, up from $42,297 loss in 2024, with no sales since December 31, 2022 and SG&A expenses jumping to $154k from public company costs offset partly by $62k liability forgiveness. Q4 showed no revenue momentum, mirroring full-year inactivity after inventory ceased in Q2 2022. Cash dwindled to nominal $4k, propped by $200k minority stockholder advances; working capital sank to $(387k). No guidance issued. Going concern doubts loom large.
8-K
Auditor switch disclosed
Acro Biomedical dismissed KCCW as its auditor on January 4, 2026, after clean reports for 2023-2024—save a going-concern warning—and tapped Weinberg as replacement. No accounting disagreements or prior consultations marred the switch. KCCW's concurrence letter attaches as Exhibit 16.1. Smooth handover, yet going concern lingers.
10-Q
Q3 FY2025 results
Acro Biomedical posted no revenue for Q3 ended September 30, 2025, with operating expenses spiking to $115,099 (up from $9,106 y/y) on public company fees, driving operating loss to $115,099 and net loss to $117,809 after $2,710 related-party interest—worse than Q3 2024's $10,229 net loss. YTD losses widened to $143,672 from $31,624 y/y, as expenses hit $137,647. Cash drained $170,925 in operations but related-party advances of $174,772 lifted quarter-end cash to $4,323; liabilities climbed to $436,942, deepening stockholders' deficit. No capex, so free cash flow not disclosed in the 10-Q. Thin cash sustains bare-bones ops. Pink sheet illiquidity stalls funding.
8-K
CEO transition at Acro Biomedical
Acro Biomedical Co., Ltd. announced the resignation of Pao-Chi Chu as director, chairman, and CEO on August 14, 2025, effective upon successor appointment, with no disagreements cited. The board immediately appointed Yu-Ting Su as director, chairman, and CEO that day. Su brings biotech expertise from roles at BioSpring and BioSeed. This leadership shift promises continuity in operations.
10-Q
Q2 FY2025 results
Acro Biomedical posted no revenue for Q2 FY2025 ended June 30, 2025, matching last year, while operating expenses climbed to $13,614 from $9,086 y/y, driving an operating loss of $13,614 up 50% y/y (derived). Net loss widened to $15,562 from $10,143 y/y, with the $5,419 gap mainly from higher imputed interest on related-party advances at $1,948 versus $1,057. YTD through June 30, 2025, net loss reached $25,863 on $22,548 operating expenses, up from $21,395 last year, fully reconciling to 60,042,000 diluted shares with no anti-dilution. Cash dwindled to $26 after $116,515 operating outflow offset by $116,065 related-party funding, leaving $241,653 due to affiliates and a $317,520 stockholders' deficit. No capex means free cash flow mirrors operating cash. Thin liquidity persists. Stock trades on Pink Limited Market with no market makers.
AACB
Artius II Acquisition Inc.
10.31+0.00
ADIA
Adia Nutrition, Inc.
0.07-0.00
AFJK
Aimei Health Technology Co., Lt
26.96-3.55
CSLMF
CSLM Acquisition Corp.
3.14+0.54
HAIAF
Healthcare AI Acquisition Corp.
12.74+0.00
PACH
Pioneer Acquisition I Corp
10.11+0.01
TACH
Titan Acquisition Corp.
10.24-0.01
TDAC
Translational Development Acqui
10.42+0.00
VACH
Voyager Acquisition Corp
10.57+0.00
WELNF
Integrated Wellness Acquisition
12.21+0.00